10/04/2019 Post-ESMO podcast

48:53
 
Share
 

Manage episode 243771600 series 2494347
By Informa Pharma Intelligence Podcast. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.
Mike Ramirez, Zach McLellan, David Dahan, and Tara Hansen discuss takeaways related to the European Society for Medical Oncology annual 2019 meeting. Topics covered in this episode include: • Mike Ramirez: Discussion of results for AMG 510 in colorectal cancer, as well as updates in first-line non-small cell lung cancer for Tecentriq, Opdivo, and Tagrisso (1:17) • Zach McLellan: PARP inhibitors dual in ovarian cancer, including updates on Zejula, Lynparza, and veliparib (17:41) • David Dahan: Phase II results for Debio 1143 combined with chemo-radiotherapy for patients with head and neck cancer and for tucatinib combined with Herceptin for patients with HER2+ colorectal cancer (27:47) • Tara Hansen: Overview on Keytruda in triple-negative breast cancer, combination regimens in hepatocellular carcinoma, and new mechanism of action drugs in renal cell carcinoma (36:00) To learn more about Datamonitor Healthcare, BioMedTracker, and other offerings from Informa Pharma Intelligence, visit: pharmaintelligence.informa.com/

54 episodes